Navigation Links
Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use
Date:5/30/2008

rapid recovery are the cornerstones to this vitally important addition to the Lutronic family of medical laser products."

MOSAIC eCO2 is designed to address a broad scope of clinical applications requiring the ablation, vaporization, excision, incision, and coagulation of soft tissue in dermatology and plastic surgery. A wide range of conditions may be treated with the highest degree of efficacy such as total skin resurfacing, treatment of fine wrinkles, rhytids, acne scars, surgical scars, and uneven pigmentation, such as lentigines and dyschromia.

The MOSAIC eCO2 Laser System utilizes a CO2 tube to generate a laser beam with a wavelength of 10.6 um. Taken together with the unique scanner hand piece, the physician can optimize the effect for different applications by controlling the power of the laser pulse and using a different scan pattern.

"The main differentiating feature of the MOSAIC eCO2 system is the 'freedom' it brings to the practitioner as well as to the patient: freedom from inferior fractional laser systems; freedom from painful treatments and questionable results; freedom to self-select depth and density of treatment; and freedom to select Static and Dynamic modes to deliver the very best results possible.

"The ability to combine two operation modes in one delivery system is particularly important when comparing MOSAIC eCO2 to other fractional CO2 lasers," continued Dr. Hwang. "Static mode offers deeper penetration and greater patient comfort, and Dynamic mode is ideal for larger area blending and smoothing. The laser works exceptionally well in medical applications because 10.6 um is near the peak of tissue water absorption, and when water in the tissue absorbs the laser energy, it heats up. This heating causes instantaneous vaporization of the target tissue. This smart system is yet another example of Lutronic's tireless efforts as the vanguard in breakthrough aesthetic and clinical laser technology."

About Lutroni
'/>"/>

SOURCE Lutronic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
2. Lutronic Inc. Announces FDA Clearance of Its Spectra VRM III Q-Switched Nd: Yag Laser System for Treating a Broad Spectrum of Dermatological and Aesthetic Conditions
3. Elbit Imaging Ltd. Announces First Quarter Results for 2008
4. ASTRO announces 2008 gold medalists
5. Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008
6. Darwin Announces Creation of New Health Care and Errors and Omissions Divisions
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Ekahau Announces Compatibility With 802.11n
9. Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
10. DRAXIS Announces Completion of Sale to Jubilant
11. WellPoint Announces Realignment of Operations, Technology and Government Services Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...ubstantially higher rates of mental health problem...s from a systematic review and meta-analysis publi...or studies over the past four decades containing d...ess people, Seena Fazel and colleagues of the Univ...,684 homeless individuals based in the US, UK, mai...
(Date:12/2/2008)...mposium today hosted by Johns,Hopkins University...s presented,the latest research in brain plastici... into technology to improve lives. Henry Mahncke, ...e that cognitive intervention developed by,Posit ...s ability to,reorganize itself throughout life. ...
(Date:12/2/2008)... assault are unsettling; the Department of Justice...e victim of attempted or actual sexual assault dur...rs from two universities, including the University...are unaware of drug-facilitated sexual assault and...including leaving drinks unattended. , "These f...
(Date:12/2/2008)...rprise software and online services veteran is exp...ers of Yugma,s instant web conferencing solutions ... December 2, 2008 -- Yugma , the leading web conf...aborate instantly using the Internet, announced th... Officer. , , ,Vas has more than 20 years of exper...
Breaking Medicine News(10 mins):Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3
... dengue cases in the national capital civic author...k the menace//, including prosecuting people who c...v, deputy municipal health officer of Delhi said, ...ted of which six proved to be fatal. We have recei...
...ealthcare treatment meted to those suffering menta...udy has found.// An investigation of 8 million hea...s opened a can of worms. The study spanning 18 m... a propensity suffer other illness alongside, as c...
...re is a “crisis” over lack of donors at sperm bank...linics being totally out of stock//, women and cou...problem. In 1990s, the highest number of donors w...decreasing. To make it worse, last year a new law ...
... reduce the bio-terrorism threat of the Venezuelan...hers at the University of Texas Medical Branch at ...al step in the development of effective drug thera...litis (VEE) virus, which is a potential bio-terror...
Other Medicine News:Health News:Shortage of donors at sperm bank clinics 2Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2
(Date:12/1/2008)...PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc...ncet , one of the world,s leading medical journals...n regulator, experimental compound tasimelteon (VE... entitled "Melatonin agonist tasimelteon (VEC-162)...o randomised controlled multicentre trials." Resul...
(Date:12/1/2008)...hatasia Treated With ENB-0040 at Children,s Hospit...MONTREAL, Dec. 1 Enobia Pharma, an...loping novel therapeutics for serious bone disorde...in its clinical program for hypophosphatasia was d...herapy (ERT) with ENB-0040 for the treatment of th...
(Date:12/1/2008)...December 1 Following a,...t to procure an MVA-based,third generation small...,Canada, on behalf of the Canadian Department of N...an Nordic for the delivery of IMVAMUNE(R). , ...R) as part of the,country,s bio-preparedness prog...
(Date:11/30/2008).... 1 Older adults who ex...w and a greater number of small blood vessels in t... the annual meeting of the Radiological Society of...ucted at the University of North Carolina ( UNC)...ns of older adults who exercise to brain scans of ...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Thyroid Hormone Could One Day Treat Osteoporosis 13954 1Thyroid Hormone Could One Day Treat Osteoporosis 13954 2Thyroid Hormone Could One Day Treat Osteoporosis 13954 3Alarming growth in expected CO2 emissions in China finds UC analysis 2451 1Alarming growth in expected CO2 emissions in China finds UC analysis 2451 2Alarming growth in expected CO2 emissions in China finds UC analysis 2451 3GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 1GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 2GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 3Injection of human umbilical cord blood helps the aging brain 13948 1Injection of human umbilical cord blood helps the aging brain 13948 2
...ay 29, 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) ...007) study of aztreonam lysine for inhalation for,...who have,pulmonary Pseudomonas aeruginosa (P. aeru...e at Day 28 from baseline in respiratory,symptoms,...Revised,(CFQ-R), a patient-reported outcome (PRO) ...
...for Organ Transplantation, HORSHOLM, Denmark, May ...a announces positive Phase I clinical results for,... Heads into US,Phase II clinical trials for organ ...:LCP) announces positive results,from its Phase I ..., once-daily tacrolimus tablet. , A series of Phas...
Other Medicine Technology:Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
MONOJECT Red/Yellow Mottled Stopper
BD Vacutainer® Specialty Tubes - Thrombin
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
Medicine Products: